TY - JOUR
T1 - Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors
T2 - Analysis of a large United States claims database
AU - Schnitzer, Thomas J.
AU - Kong, Sheldon X.
AU - Mavros, Panagiotis
AU - Straus, Walter L.
AU - Watson, Douglas J.
N1 - Funding Information:
This study was sponsored by Merck & Co, Inc, Whitehouse Station, New Jersey.
PY - 2001
Y1 - 2001
N2 - Background: Previous studies have shown that 20% to 40% of patients requiring nonsteroidal anti-inflammatory drugs (NSAIDs) are concomitantly prescribed gastroprotective agents (GPAs) such as proton pump inhibitors (PPIs) and H2-receptor antagonists. Objective: The purpose of this study was to examine NSAID prescription patterns and the concurrent use of GPAs in a large national sample of patients who were prescribed NSAIDs for the first time. Methods: Patterns of NSAID use, particularly chronic NSAID use, and of concomitant use of GPAs were examined using a large US-based prescription database. Patients with at least 1 NSAID prescription dispensed between May 1 and August 31, 1998, were identified. Persons with any NSAID prescription within 4 months prior to the first (index) prescription were excluded. The remaining patients were defined as new NSAID users and then classified as chronic users (≥30 days of supply of NSAIDs during the 120 days of follow-up after the first NSAID prescription) or acute users (<30 days of NSAID supply during the 120 days of follow-up). Concomitant GPA use was defined as receipt of any GPA prescription between the fill date of NSAID prescription and 125% of days of supply. NSAIDs included diclofenac/misoprostol (in a fixed combination), diclofenac, naproxen, nabumetone, ibuprofen, and "other" (comprising several less frequently prescribed agents). Patients were classified as users of a particular NSAID based on the first NSAID prescription they received. GPAs included PPIs, H2-receptor antagonists, and misoprostol.
AB - Background: Previous studies have shown that 20% to 40% of patients requiring nonsteroidal anti-inflammatory drugs (NSAIDs) are concomitantly prescribed gastroprotective agents (GPAs) such as proton pump inhibitors (PPIs) and H2-receptor antagonists. Objective: The purpose of this study was to examine NSAID prescription patterns and the concurrent use of GPAs in a large national sample of patients who were prescribed NSAIDs for the first time. Methods: Patterns of NSAID use, particularly chronic NSAID use, and of concomitant use of GPAs were examined using a large US-based prescription database. Patients with at least 1 NSAID prescription dispensed between May 1 and August 31, 1998, were identified. Persons with any NSAID prescription within 4 months prior to the first (index) prescription were excluded. The remaining patients were defined as new NSAID users and then classified as chronic users (≥30 days of supply of NSAIDs during the 120 days of follow-up after the first NSAID prescription) or acute users (<30 days of NSAID supply during the 120 days of follow-up). Concomitant GPA use was defined as receipt of any GPA prescription between the fill date of NSAID prescription and 125% of days of supply. NSAIDs included diclofenac/misoprostol (in a fixed combination), diclofenac, naproxen, nabumetone, ibuprofen, and "other" (comprising several less frequently prescribed agents). Patients were classified as users of a particular NSAID based on the first NSAID prescription they received. GPAs included PPIs, H2-receptor antagonists, and misoprostol.
KW - Gastroprotective agents
KW - Misoprostol
KW - Nonsteroidal anti-inflammatory drugs
KW - Prescription patterns
KW - Proton pump inhibitors
UR - http://www.scopus.com/inward/record.url?scp=0035692914&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035692914&partnerID=8YFLogxK
U2 - 10.1016/S0149-2918(01)80151-X
DO - 10.1016/S0149-2918(01)80151-X
M3 - Article
C2 - 11813933
AN - SCOPUS:0035692914
SN - 0149-2918
VL - 23
SP - 1984
EP - 1998
JO - Clinical Therapeutics
JF - Clinical Therapeutics
IS - 12
ER -